This company is no longer active
Humanigen Past Earnings Performance
Past criteria checks 0/6
Humanigen's earnings have been declining at an average annual rate of -42.3%, while the Biotechs industry saw earnings growing at 16.9% annually. Revenues have been growing at an average rate of 67.8% per year.
Key information
-42.3%
Earnings growth rate
-8.8%
EPS growth rate
Biotechs Industry Growth | -14.6% |
Revenue growth rate | 67.8% |
Return on equity | n/a |
Net Margin | -3,156.8% |
Last Earnings Update | 31 Mar 2023 |
Recent past performance updates
No updates
Recent updates
Revenue & Expenses Breakdown
How Humanigen makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
31 Mar 23 | 2 | -54 | 15 | 0 |
31 Dec 22 | 3 | -71 | 16 | 0 |
30 Sep 22 | 3 | -109 | 16 | 26 |
30 Jun 22 | 4 | -152 | 19 | -97 |
31 Mar 22 | 4 | -192 | 23 | -60 |
31 Dec 21 | 4 | -237 | 23 | 0 |
30 Sep 21 | 3 | -235 | 23 | 0 |
30 Jun 21 | 2 | -199 | 25 | 123 |
31 Mar 21 | 1 | -153 | 19 | 59 |
31 Dec 20 | 0 | -90 | 16 | 0 |
30 Sep 20 | 0 | -59 | 13 | 0 |
30 Jun 20 | 0 | -31 | 6 | 1 |
31 Mar 20 | 0 | -10 | 6 | 3 |
31 Dec 19 | 0 | -10 | 6 | 3 |
30 Sep 19 | 0 | -10 | 6 | 3 |
30 Jun 19 | 0 | -10 | 7 | 3 |
31 Mar 19 | 0 | -9 | 7 | 2 |
31 Dec 18 | 0 | -12 | 9 | 2 |
30 Sep 18 | 0 | -13 | 10 | 3 |
30 Jun 18 | 0 | -18 | 10 | 6 |
31 Mar 18 | 0 | -22 | 9 | 9 |
31 Dec 17 | 0 | -22 | 8 | 11 |
30 Sep 17 | 0 | -24 | 7 | 13 |
30 Jun 17 | 0 | -21 | 8 | 11 |
31 Mar 17 | 0 | -27 | 9 | 11 |
31 Dec 16 | 0 | -27 | 8 | 10 |
30 Sep 16 | 0 | -35 | 11 | 11 |
30 Jun 16 | 0 | -37 | 11 | 13 |
31 Mar 16 | 0 | -31 | 11 | 12 |
31 Dec 15 | 0 | -35 | 13 | 15 |
30 Sep 15 | 0 | -32 | 10 | 19 |
30 Jun 15 | 0 | -33 | 10 | 20 |
31 Mar 15 | 0 | -37 | 11 | 24 |
31 Dec 14 | 0 | -38 | 10 | 27 |
30 Sep 14 | 0 | -39 | 10 | 19 |
30 Jun 14 | 0 | -42 | 10 | 14 |
31 Mar 14 | 0 | -44 | 9 | 8 |
31 Dec 13 | 0 | -42 | 8 | 0 |
30 Sep 13 | 0 | -43 | 8 | 0 |
30 Jun 13 | 0 | -41 | 7 | 0 |
31 Mar 13 | 3 | -31 | 6 | 0 |
31 Dec 12 | 6 | -24 | 5 | 0 |
Quality Earnings: 0KB2 is currently unprofitable.
Growing Profit Margin: 0KB2 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 0KB2 is unprofitable, and losses have increased over the past 5 years at a rate of 42.3% per year.
Accelerating Growth: Unable to compare 0KB2's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 0KB2 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-26.8%).
Return on Equity
High ROE: 0KB2's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.